Status: Not yet recruiting
A Study of Vepugratinib (LY3866288) in Adults With Non-Muscle Invasive Bladder Cancer and Upper Tract Urothelial Cancer
The main purpose of this study is to see how well vepugratinib works in adults with low grade, intermediate risk, non-muscle invasive bladder cancer (LG IR NMIBC) or low-grade upper tract urothelial carcinoma (LG UTUC). Safety tests will also be conducted. For each participant, the study will last up to 5 years.
Participants needed: 161
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Eli Lilly and CompanyUpdated: Oct 8, 2026Locations: 1
Eligibility criteria
Have a PS of 0 to 2 on the Eastern Cooperative Oncology Group Performance Status... [+6]
All Participants [+8]